AU2023395547A1 - 2-azabicyclo[3.1.1]heptane compound - Google Patents

2-azabicyclo[3.1.1]heptane compound

Info

Publication number
AU2023395547A1
AU2023395547A1 AU2023395547A AU2023395547A AU2023395547A1 AU 2023395547 A1 AU2023395547 A1 AU 2023395547A1 AU 2023395547 A AU2023395547 A AU 2023395547A AU 2023395547 A AU2023395547 A AU 2023395547A AU 2023395547 A1 AU2023395547 A1 AU 2023395547A1
Authority
AU
Australia
Prior art keywords
group
atom
methyl
compound
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023395547A
Other languages
English (en)
Inventor
Koji Abe
Masahiro Inoue
Masaharu Inui
Jun Kobayashi
Shunsuke MAEHARA
Kaoru Matsushita
Naohiro Takemoto
Akitake Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of AU2023395547A1 publication Critical patent/AU2023395547A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2023395547A 2022-12-16 2023-12-15 2-azabicyclo[3.1.1]heptane compound Pending AU2023395547A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-201488 2022-12-16
JP2022201488 2022-12-16
PCT/JP2023/044987 WO2024128305A1 (ja) 2022-12-16 2023-12-15 2-アザビシクロ[3.1.1]ヘプタン化合物

Publications (1)

Publication Number Publication Date
AU2023395547A1 true AU2023395547A1 (en) 2025-06-26

Family

ID=91485946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023395547A Pending AU2023395547A1 (en) 2022-12-16 2023-12-15 2-azabicyclo[3.1.1]heptane compound

Country Status (8)

Country Link
EP (1) EP4635944A1 (cg-RX-API-DMAC7.html)
JP (1) JPWO2024128305A1 (cg-RX-API-DMAC7.html)
KR (1) KR20250112793A (cg-RX-API-DMAC7.html)
CN (1) CN120603816A (cg-RX-API-DMAC7.html)
AU (1) AU2023395547A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025006722A (cg-RX-API-DMAC7.html)
TW (1) TW202430169A (cg-RX-API-DMAC7.html)
WO (1) WO2024128305A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260012686A (ko) * 2024-07-18 2026-01-27 (주)셀트리온 신규한 오렉신 2 수용체 작용제 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015056100A2 (en) 2013-10-14 2015-04-23 Marvell World Trade Ltd. Systems and methods for graphics process units power management
SG11201604639YA (en) 2013-12-12 2016-07-28 Univ Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
JP6359924B2 (ja) 2014-09-17 2018-07-18 トヨタ自動車株式会社 非接触送受電システム
SG11201806429PA (en) 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
US10428023B2 (en) * 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CA3074059A1 (en) * 2017-09-01 2019-03-07 Chronos Therapeutics Limited Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
WO2019081939A1 (en) * 2017-10-25 2019-05-02 Chronos Therapeutics Limited 2-AZABICYCLO [3.1.1] DERIVATIVES AS ANTAGONISTS OF OREXIN-1 AND OREXIN-2 RECEPTORS
PE20211700A1 (es) * 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co Compuesto heterociclico y su uso
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
PE20221730A1 (es) 2019-11-27 2022-11-07 Sumitomo Pharma Co Ltd Derivado de cicloalquilurea
CN119235864A (zh) 2020-07-17 2025-01-03 卫材R&D管理有限公司 取代的哌啶化合物及其用途
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
CN116969888A (zh) * 2022-04-24 2023-10-31 优领医药科技(上海)有限公司 含环丙基并环类衍生物、其药学上可接受的盐及其制备方法和应用

Also Published As

Publication number Publication date
CN120603816A (zh) 2025-09-05
JPWO2024128305A1 (cg-RX-API-DMAC7.html) 2024-06-20
EP4635944A1 (en) 2025-10-22
WO2024128305A1 (ja) 2024-06-20
KR20250112793A (ko) 2025-07-24
TW202430169A (zh) 2024-08-01
MX2025006722A (es) 2025-07-01

Similar Documents

Publication Publication Date Title
AU2018243463C1 (en) 11,13-modified saxitoxins for the treatment of pain
EP3601290B1 (en) 11,13-modified saxitoxins for the treatment of pain
TW202311260A (zh) 含有亞磺醯亞胺基的atr抑制劑化合物
US20220009938A1 (en) 11,13-modified saxitoxins for the treatment of pain
JP5860199B2 (ja) Nk1アンタゴニストとしてのピロリジンおよびピペリジンの誘導体
TW201204346A (en) Novel hydroxamic acid derivative
CN105829286A (zh) 作为lta4h抑制剂的杂芳基丁酸衍生物
UA123071C2 (uk) ІНГІБІТОРИ ДОФАМІН-<font face="Symbol">b</font>-ГІДРОКСИЛАЗИ
WO2023059792A1 (en) Coronavirus non-structural protein 3 degrading compounds
CA3234990A1 (en) Rxfp1 agonists
Žukauskaitė et al. Synthesis of new functionalized aziridine-2-and azetidine-3-carboxylic acid derivatives of potential interest for biological and foldameric applications
WO2025160286A1 (en) 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
TW202304864A (zh) 1,3-取代的環丁基衍生物及其用途
TWI501953B (zh) 環己烷衍生物化合物
TW202430169A (zh) 2-氮雜雙環[3.1.1]庚烷化合物
WO2023107487A1 (en) Lonp1 inhibitor compounds, uses and methods
CA3180417A1 (en) Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid
EP4685151A1 (en) Proteasome inhibitor
TW201625588A (zh) 環狀胺衍生物
HK40120402A (en) Dihydrooxadiazinone compound and pharmaceutical use thereof
RU2778455C2 (ru) 11,13-модифицированные сакситоксины для лечения боли
EP4541791A1 (en) Dihydrooxadiazinone compound and pharmaceutical use thereof
EP4709486A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
TWI670262B (zh) 新穎雜芳基丁酸衍生物
CA3253076A1 (en) COMPOUNDS AND PROCESSES FOR DEGRADING CASEIN KINASE 1 ALPHA